Top Story

Daclatasvir with PEG-IFN a-2a/ribavirin reduced treatment time for HCV

January 30, 2015

In a phase 2b clinical trial, a regimen of daclatasvir combined with pegylated interferon alfa-2a and ribavirin was safe and generally well tolerated among patients with hepatitis C virus genotype 2 and 3 infections, as well as reduced the duration of treatment, according to study data.

Researchers randomly assigned 151 patients with HCV genotype 2 (n=71) or 3 (n=80) infection to 60 mg daclatasvir (Bristol-Myers Squibb) for 12 or 16 weeks or placebo for 24 weeks, both combined with PEG-IFN a-2a and ribavirin. Fifty patients were in the 12-week group, 50 were in the 16-week group and 51 received placebo. Treatment duration was extended to 24 weeks if patients did not achieve an early virologic response.

In the Journals

Monovalent Ebola vaccine appeared safe in early trial

January 30, 2015
The results of a phase 1 clinical trial suggest a monovalent Ebola vaccine was safe and immunogenic in healthy adults, according to recently published…
Oseltamivir reduced influenza symptoms, complications in adults In the Journals

Oseltamivir reduced influenza symptoms, complications in adults

January 29, 2015
An independent research group found that oseltamivir shortened the duration of influenza symptoms by approximately 1 day and reduced the risk for influenza…
Anne Schuchat

As measles count rises, CDC encourages MMR vaccination

January 29, 2015
Since Jan. 1, 84 cases of measles across 14 states have been reported, 67 of which have been linked to the outbreak stemming from Disneyland resort theme parks…
FDA News

FDA designates Neutrolin as QIDP

January 29, 2015
The FDA has designated a novel formulation as a qualified infectious disease product, for the prevention of catheter-related bloodstream infections for oncology…
More News Headlines »
Regimen Selection in HIV

Regimen Selection in HIV: Considering New Options to Optimize Outcomes

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than 2 decades into the antiretroviral therapy (ART) era, numerous options are available for HIV treatment. The…
More »
Meeting News Coverage Video
thumbnail for video 3911388507001

Student education, immunization requirements necessary to prevent outbreaks on college campuses

November 28, 2014
NEW YORK — James C. Turner, MD, executive director of the department of student health and the National Social…
More »
HCV Consults: Volume 1, Number 3

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »